Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent  by Yamauchi, Paul S. et al.
Systematic review of efficacy of antietumor
necrosis factor (TNF) therapy in patients
with psoriasis previously treated with
a different antieTNF agent
Paul S. Yamauchi, MD, PhD,a,b Robert Bissonnette, MD,c Henrique D. Teixeira, PhD, MBA,d
and Wendell C. Valdecantos, MDd
Santa Monica and Los Angeles, California; Montreal, Quebec, Canada; and North Chicago, IllinoisFrom
M
M
Re
Liter
In
G
Ph
th
Discl
fr
A
Li
Pf
fr
A
612Background: Tumor necrosis factor (TNF) antagonists have improved outcomes for patients with
psoriasis, but some patients are unresponsive to treatment (primary failure) or lose an initially effective
response (secondary failure).Objective: We sought to systematically investigate the efficacy and safety of a second TNF antagonist after
failure of a first TNF antagonist.Methods: Published primary studies evaluating the efficacy of switching TNF antagonists after failure were
systematically extracted.Results: Fifteen studies were included. Although response rates to a second TNF antagonist were lower than
for a first, a substantial proportion of patients in every study achieved treatment success. Week-24 response
rates for a second antagonist were 30% to 74% for a 75% improvement in Psoriasis Area and Severity Index
score and 20% to 70% for achieving a Physician Global Assessment score of 0/1; mean improvements in
Dermatology Life Quality Index ranged from 3.5 to 13. In general, patients who experienced secondary
failure achieved better responses than patients with primary failure. Adverse event incidences ranged from
20% to 71%, without unexpected adverse events; 0% to 11% of patients experienced serious adverse events.Limitations: There was no common definition of treatment failure across these studies of varied design.Conclusions: Some patients benefit from switching to a second TNF antagonist after failure of a first TNF
antagonist, with improved quality of life. ( J Am Acad Dermatol 2016;75:612-8.)
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approved by the US Food and Drug Administration
(in 2004) to treat plaque psoriasis, is a recombinant
fusion protein combining soluble human TNF re-
ceptors linked to the fragment crystallizable portion
of an IgG1 molecule. Infliximab (approved in 2006)
and adalimumab (approved in 2008) are recombi-CAPSULE SUMMARY
d In patients with psoriasis, guidelines are
needed for alternative treatment in
patients who do not respond to antie
tumor necrosis factor agents.
d In this systematic review, some patients
who failed treatment with 1 antietumor
necrosis factor agent successfully
responded to another.
d Switching to another antietumor
necrosis factor agent may be considered
in nonresponsive patients.nant IgG1 monoclonal anti-
bodies, but they differ in
origin; infliximab is a humane
murine chimeric molecule,
whereas adalimumab is fully
human.Certolizumab is a TNF
inhibitor (humanized anti-
body fragment conjugated to
polyethylene glycol) that is
currently being evaluated in
phase III studies of psoriasis;
golimumab is a fully human
monoclonal antieTNF anti-
body that is approved for
multiple indications but not
psoriasis.
Despite the effectiveness
of TNF antagonists in the treatment of psoriasis,
some patients never achieve an initial response to
treatment (primary failure), whereas others lose their
initial response over time (secondary failure).
Clinical observations, trials, and individual cases
suggest that switching to a treatment with a different
mechanism of action is sometimes unnecessary and
that switching to a different TNF antagonist, specif-
ically after secondary failure, is often successful in
regaining a response. There is no consensus on the
best approach for switching treatment after failure of
an antieTNF agent, partly because, to our knowl-
edge, the data were never organized and systemat-
ically analyzed. Here, we systematically review data
from clinical studies assessing the efficacy of switch-
ing to a TNF antagonist after failure with an initial
TNF antagonist to help guide clinical treatment of
patients with unsatisfactory response to prior
antieTNF therapy.
METHODS
Searches of the Cochrane Library, MEDLINE,
EMBASE, EMBASE Alert, BIOSIS Previews,
SciSearch, International Pharmaceutical Abstracts,
and Derwent Drug File were conducted to identify
clinical studies that evaluated TNF antagonists for the
treatment of moderate to severe psoriasis in adults
who previously experienced treatment failure with
another TNF antagonist. The searches encompassed
the literature through February 18, 2015. Search
terms were based on specific agents (‘‘adalimumab,’’‘‘Humira,’’ ‘‘certolizumab,’’ ‘‘Cimzia,’’ ‘‘etanercept,’’
‘‘Enbrel,’’ ‘‘golimumab,’’ ‘‘Simponi,’’ ‘‘infliximab,’’
and ‘‘Remicade’’) and mechanism of action (‘‘anti
TNF,’’ ‘‘anti TNF agent*,’’ ‘‘anti TNF alpha,’’ ‘‘TNF
alpha antagonist*,’’ ‘‘TNF alpha antibody*,’’ ‘‘TNF
alpha blockade,’’ ‘‘TNF alpha inhibitor*,’’ ‘‘tumor
necrosis factor antagonist*,’’ ‘‘tumor necrosis factorblocker,’’ ‘‘tumor necrosis
factor inhibitor*,’’ ‘‘tumour
necrosis factor antagonist*,’’
‘‘tumour necrosis factor in-
hibitor*’’). Case reports (but
not case series), cost eco-
nomic analyses, and reviews
were excluded. Studies
reporting results only in pa-
tients with psoriatic arthritis
were manually removed, as
were pediatric trials and
studies in which most pa-
tients switched treatments
for nonmedical reasons (eg,
insurance reimbursement).
Included studies must havereported the percentage of patients achieving a
Physician Global Assessment (PGA) score of 0 or 1,
50% improvement in Psoriasis Area and Severity
Index (PASI) score (PASI50), or 75% improvement in
PASI score (PASI75).7
Overall, 334 articles were retrieved in the initial
and follow-up searches; 2 additional related
articles were subsequently found. After manually
screening for the inclusion and exclusion criteria
described above, 24 full-text articles were obtained.
Nine additional articles were removed based on
exclusion criteria (efalizumab treatment [n = 3], all
patients having psoriatic arthritis [n = 2], lack of
efficacy data [n = 1], lack of prior treatment with
biologics [n = 1], overlapping study [n = 1], and
review [n = 1]), leaving 15 full-text articles for the
analysis.
RESULTS
Study designs and patients
Fifteen studies were analyzed (Table I; available at
http://www.jaad.org). All patients from the included
studies had moderate to severe plaque psoriasis.
Most patients were men (range, 50%-80%; median,
65%). Studies differed by length, prevalence of
concomitant psoriatic arthritis, duration of first TNF
antagonist washout, and definitions of treatment
failure. Six studies explicitly allowed concomitant
methotrexate; however, the number of patients
receiving concomitant methotrexate therapy was
generally low (range, 3%-32%).8-13
Abbreviations used:
DLQI: Dermatology Life Quality Index
PASI: Psoriasis Area and Severity Index
PASI50: 50% improvement in Psoriasis Area and
Severity Index score
PASI75: 75% improvement in Psoriasis Area and
Severity Index score
PGA: Physician Global Assessment
TNF: tumor necrosis factor
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Efficacy endpoints included aPGA score of 0/1 (or
corresponding clear/minimal) in 7 studies8-10,14-17
and a PASI75 response in 11 studies8,9,11-13,15,18-22;
6 studies11,14,16,17,20,22 had extractable Dermatology
Life Quality Index (DLQI) scores for patients who
failed prior therapies (Figs 1 and 2, and Table II;
available at http://www.jaad.org). Two studies
compared switching among multiple TNF inhibitors:
the Italian Psocare Registry reported switching
among any starting and ending combination of
adalimumab, etanercept, and infliximab,21 and
another study reported switching from adalimumab
or infliximab to etanercept.16Switching from etanercept to adalimumab
Seven studies investigated switching from
etanercept to adalimumab,11-15,19,20 and 3 other
studies analyzed a mixed group of switches that
included etanercept to adalimumab.8,18,21 Of these,
3 studies reported PGA outcomes (Fig 1, A).8,14,15
Two studies, specifically designed to include only
patients with prior etanercept failure who would
switch to adalimumab, reported PGA score 0/1 rates
of 49% at 16 weeks (n = 82)14 and 46% at 24 weeks
(n = 85)15; an open-label study of patients switching
to adalimumab from multiple antieTNF therapies
reported that 21% of the 14 patients switching from
etanercept to adalimumab achieved a PGA score of
0/1 at weeks 16 and 24.8
The PASI75 response rates varied among studies,
from 27% to 77% after 12 to 24 weeks of adalimumab
therapy (Fig 1, B).8,11-13,15,18-21 Two of the 3 studies
that reported results for later time points ($48weeks;
n = 30 and n = 12)12,19 showed increased rates with
longer adalimumab treatment, whereas the other
(n = 35) reported a similar rate over time.13 In one
of the studies with increasing rates, the investigator
could shorten the treatment interval of adalimumab
to 40mgonceweekly or every 10 days.12DLQI scores
improved in the 3 studies that reported this outcome
(Fig 2); scores decreased by means of 3.8 and 4.9
points in the 2 larger studies (n = 82 and n = 14)11,14
after 16 weeks of adalimumab treatment.Switching from etanercept to infliximab
In a prospective study (PSUNRISE) of 215 patients
with an inadequate response to etanercept who
switched to infliximab, 65% of patients at 10 weeks
and 61%of patients at 26weeks achieved a PGA score
of 0/1 (Fig 1, C ).9 A smaller study (n = 19) reported a
lower PGA score 0/1 rate (37%) after 12 weeks.10
PASI75 rates in PSUNRISE were 52% and 55% at 10
and 12 weeks, respectively (Fig 1, D).9 In a smaller
(n = 38) prospective study (TANGO) of patients who
experienced primary etanercept failure,22 PASI75
rates were 71% at week 10 of infliximab therapy,
94% at week 18, and 74% at week 24. The only other
study reporting PASI75 rates for patients switching
from etanercept to infliximab also included patients
switching from adalimumab (total, n = 39); rateswere
27% and 40% at weeks 16 and 24 after infliximab
treatment, respectively.21 Across studies, PASI50 rates
were 65% or more after 10 to 26 weeks of therapy.9,22
In patients with etanercept failure who switched to
infliximab, a DLQI score of 0/1 was achieved by 44%
at week 10 and 41% at week 26 of the PSUNRISE
study, corresponding to a decrease in DLQI score of
7.1 and 7.5, respectively.9 The TANGO study noted a
mean decrease in DLQI score of 13 points after
24 weeks of switching to infliximab therapy (Fig 2).22
Switching from adalimumab to etanercept
Two prospective studies included only patients
switching from adalimumab to etanercept (Fig 1, E ).
In 1 study, 20% of patients with primary adalimumab
failure (n = 30) achieved PGA scores of 0/1 at both
weeks 12 and 24; for patients with secondary
adalimumab failure (n = 37), rates were 38% and
35%, respectively.16 Corresponding mean DLQI
score reductions at week 24 were 3.5 and 6.4 points
for patients with primary and secondary failure,
respectively. In the other study (n = 10), patients
with primary adalimumab failure achieved PGA
scores of 0/1 at a rate of 50% at week 12 and 70%
at week 24, accompanied by DLQI score reductions
of 5.8 and 5.1 points, respectively.17
One additional study included patients who had
an unsatisfactory response to either infliximab or
adalimumab and then received treatment with
etanercept (n = 23); a PASI75 response was reported
in 14% and 30% of patients at 16 and 24 weeks,
respectively.21
Switching from adalimumab to infliximab
Only 1 study reported patients with an unsatis-
factory response to adalimumab switching to
treatment with infliximab; however, patients with
an unsatisfactory response to prior etanercept were
also included (total, n = 39) in the reported PASI75
Fig 1. Percentage of patients achieving Physician Global Assessment (PGA) score 0/1 or 75%
improvement in Psoriasis Area and Severity Index score (PASI75) by type of treatment switch
with 3 or more included studies. Achievement of: PGA score 0/1 in patients switching from
etanercept (ETA) to adalimumab (ADA) (A), PASI75 in patients switching from ETA to ADA (B),
PGA score 0/1 in patients switching from ETA to infliximab (IFX ) (C), PASI75 in patients
switching from ETA to IFX (D), and PGA score 0/1 in patients switching from ADA to ETA (E).
Fig 2. Mean decrease in Dermatology Life Quality Index
(DLQI ) scores in studies with extractable DLQI data.
ADA, Adalimumab; ETA, etanercept; IFX, infliximab.
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24 of infliximab therapy.21
Switching from infliximab to etanercept
A small (n = 14) prospective study of patients
who experienced secondary failure with infliximabreported a PGA score of 0/1 in 36% of patients after
both 12 and 24 weeks of etanercept treatment, and a
6.7-point meanDLQI score reduction at the later time
point.16 Another study pooled data from patients
with infliximab or adalimumab treatment failure
(n = 23) before being switched to etanercept;
PASI75 response rates were 14% at week 16 and
30% at week 24.21Switching from infliximab to adalimumab
No studies reported independent results for
infliximab failure followed by a switch to
adalimumab. A registry study (n = 43; 18 patients
who switched from infliximab to adalimumab and
25 patients who switched from etanercept to
adalimumab) reported combined PASI75 response
rates of 38% and 58% at 16 and 24 weeks,
respectively.21 A prospective study (PRIDE)8
included 3 patients who switched from infliximab
to adalimumab; PASI75 rates (pooled with patients
who had failed initial etanercept therapy [n = 14])
were 71% and 59% at weeks 16 and 24 after
adalimumab therapy, respectively.
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Several studies in this review that included
patients with primary and secondary failure to an
initial TNF inhibitor compared outcomes between
these groups. In the BELIEVE subanalysis, 80 patients
had primary nonresponse and 99 patients had sec-
ondary nonresponse to etanercept or infliximab and
were subsequently switched to adalimumab; PASI75
response rates at week 16 were 66% for secondary
nonresponders and 54% for primary non-
responders.18 Across multiple switch types exam-
ined in the Psocare Registry, secondary loss of
efficacy was associated with the achievement of
PASI75 response with a second TNF antagonist in
both univariate and multivariate analyses.21
Switching between specific antieTNF agents was
examined. After 24 weeks of adalimumab therapy,
46% of primary (n = 50) and 46% of secondary
(n = 35) nonresponders to etanercept achieved a
PGA score of 0/1 in 1 study; PASI75 response rates at
this time point were 52% and 63% for primary and
secondary nonresponders, respectively.15 In a
retrospective single-center analysis, rates of PASI50
response after 12 weeks of adalimumab treatment
were nearly identical among primary (11/16 [69%])
and secondary (11/17 [65%]) nonresponders to prior
etanercept treatment.13 In contrast, another
retrospective study found that a lower proportion
of primary nonresponders to etanercept (6/11 [55%])
achieved a PASI50 response after 12 weeks of
adalimumab therapy compared with secondary
nonresponders (11/14 [79%]).12
In a study examining the opposite switch type (ie,
adalimumab to etanercept), 20% of primary (n = 30)
and 38% of secondary (n = 37) nonresponders
achieved a PGA score of 0/1 after 12 weeks.16 In a
smaller study, most patients were deemed to be good
responders to infliximab (by outcomes including
PGA score and affected body surface area),
regardless of whether they were primary (2/2
[100%]) or secondary (12/14 [86%]) nonresponders
to etanercept.10
Intolerance
Two studies reported efficacy specifically for
patients who were intolerant to their first TNF
antagonist, defined as cessation of treatment caused
by side effects. In a prospective registry, of
3 patients who were intolerant to etanercept,
1 was subsequently a primary nonresponder to
adalimumab and 2 were primary responders (for a
66% response rate).12 In a subanalysis of the BELIEVE
study, of patients with intolerance to a prior
TNF antagonist (n = 16), 50% achieved PASI75 at
week 16.18Safety
Adverse event rates after switching TNF
antagonist agents, when reported, varied widely
among studies (20%-71%); serious adverse event
rates also varied widely (0%-11% of patients)
(Table III; available at http://www.jaad.org).
Infections occurred in all but 1 study19 (of patients
switching from etanercept to adalimumab); howev-
er, incidences or rates of infections were not always
reported. Many studies specified that no demyelin-
ation, tuberculosis, or lupus or lupuslike syndromes
occurred in patients switching between TNF
antagonists. No safety signals were observed as a
specific consequence of changing TNF agents.
Notably, no studies reported on adverse events of a
second TNF antagonist specifically in patients who
failed a first TNF antagonist owing to intolerance.
DISCUSSION
Currently, there are no specific guidelines on how
or when to switch patients who experience failure
with TNF inhibitor therapy to another biologic agent,
or which agent should be selected. In our systematic
assessment, we found that switching among all TNF
inhibitor treatments permitted achievement of PGA
scoresof 0/1or a PASI75 response in at least a subset of
patients. Although DLQI outcomes were infrequently
reported, studies that did report DLQI score observed
improvements falling within the range that Shikiar
et al23 considered to be the minimum clinically
important difference (2.3-5.7 points). Variation among
trials could be influenced by different study designs;
for example, a longer washout between TNF inhibi-
tors would likely raise the baseline DLQI score,
potentially increasing the magnitude of the change
after switching treatments. No unexpected or con-
cerning safety findings were noted, despite washout
periods for the previous TNF inhibitor that were
usually shorter than in phase III clinical trials.
The observed range of PASI75 response rates was
generally lower than rates reported for first-line
treatment with TNF inhibitors in clinical trials (eg,
71%-80% of patients treated with adalimumab
achieved a PASI75 response at 16 weeks).1-6
Although high response rates were observed in
smaller studies, rates from the largest and
best-controlled studies9,18 reported PGA score
achievement of 0/1 in 65% of patients switching to
a second TNF inhibitor for 10 weeks, and PASI75
achievement in 52% to 66% of patients after 16 to
26 weeks. Interestingly, the Italian Psocare
Registry was the only study to report PASI75
response for multiple second TNF inhibitors,
with rates of 14%, 27%, and 38% after
16 weeks of therapy with etanercept, infliximab,
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differing study designs, direct comparisons cannot
be made; however, it is reassuring that a second TNF
inhibitor treatment improved outcomes in patients in
a real-world setting versus those typically included in
clinical trials.
Prior studies in patients with rheumatoid arthritis
and ankylosing spondylitis suggest that response to a
second TNF antagonist may depend on the reason
for failure with the first antagonist, with secondary
loss of efficacy conferring an advantage over primary
inefficacy.24,25 Despite the fact that not all studies
examined the same outcome (ie, PGA score of 0/1 or
PASI50 or PASI75 achievement), the bulk of evidence
in our literature assessment suggests that patients
with secondary failure are subsequently more likely
to respond to treatment with a different TNF inhibitor
than patients with primary failure.
The lack of a common definition of treatment
failure among studies provides little insight
regarding when a clinician should consider a first
TNF antagonist to have failed. End points such as
PASI scores that were commonly measured in these
studies are cumbersome and not commonly used in
clinical practice. Therefore, assessing loss of
response to therapy may be incumbent on the
clinician’s preferential set of parameters that are
easier to measure, such as body surface area or
PGA. Patient-reported outcomes including DLQI
scores and patient dissatisfaction because of relapse
of psoriasis and symptoms can also be used when
deciding whether to switch therapy.
Differences in study designs (Table I) precluded
conducting a meta-analysis or making direct com-
parisons between studies. For example, washout
periods were not standardized among studies. A lack
of washout may mean that early outcomes reflect
additive or synergistic effects of TNF inhibitors
because of the long half-lives of these biologic
agents. Alternatively, the defined length of time
before determining ‘‘failure’’ may have been too
short in some included studies. For example, a
previous study showed that patients receiving eta-
nercept had a PASI75 response rate of 49% at
12 weeks, which increased to 59% by week 241;
possibly, some patients from the included studies
simply needed extended TNF inhibitor exposure to
achieve a response. Indeed, in most studies, PASI75
response rates increased over time, and were highest
after 48 or 52 weeks of adalimumab therapy after
etanercept failure in 212,19 of 3 studies reporting data
at those time points (the other reported maintenance
of effect13). It is unclear whether this was because of
enhanced efficacy of the biologic beyond 12 weeks,
dosing adjustments, or addition of concomitantpsoriasis treatments in patients with a lower
response. Another limitation of our review is that
most studies included patients switching from
etanercept, limiting generalizability; however,
similar trends were observed for switching from
other TNF antagonists. Furthermore, this review is
limited by potential publication bias; studies may not
have been published if data on the efficacy of a
second TNF antagonist were negative. Other
limitations include the small numbers of patients in
most studies, and short study durations; in addition,
many studies were retrospective or open-label in
design.
Conclusions
This systematic literature review suggests that a
lack of response to an initial TNF antagonist does not
preclude patients from responding favorably to a
subsequent TNF antagonist. Switching patients who
are not responding to treatment with an antieTNF
agent to another TNF antagonist can be considered
as a therapeutic option that may produce clinically
meaningful responses in a substantial proportion of
patients, with improved quality of life.
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Table I. Characteristics of included studies
Study N Men, %
Mean
age, y
Mean disease
duration, y
PsA
history,
% Study type
Study
duration
Washout
period
Mean duration
of first TNF
antagonist Failure definition
ETA to ADA
Strober
et al,14
2011
82 57 48 6 14 17 6 12 57 Substudy of
prospective
OL study
16 wk 11-17 d Median, 20 mo PGA score $2 after $6 mo
of therapy or $3 mo of
therapy ‘‘with deterioration
of efficacy as determined
and documented by the
treating physician’’
Bissonnette
et al,15
2010*
85 71 NR NR NR Prospective OL 24 wk 0 NR PGA score $2 after $3 mo of
therapy or achieving PGA
score 0/1 after $3 mo of
therapy but loss of PGA
score 0/1 after step-down
dosing
Fonseca
et al,13
2015
35 77 53 24 57 Retrospective
single-center
52 wk 0 82.8 6 72.5 wk 18: Not achieving PASI50 at wk
12 of therapy
28: Loss of PASI50 response
12 wk after having achieved
PASI50 at wk 12
Intolerance: cessation of
treatment because of AEs
van L€umig
et al,12
2010
30 63 52 6 12 26 6 12 30 Registry data
extraction
48 wk 0-22 mo
(Mean, 2 mo)
2.1 6 1.3 y 18: Not achieving PASI50 at wk
12 of therapy
28: Loss of response in a patient
who achieved PASI50 at wk 12
Intolerance: cessation of
treatment because of AEs
Woolf
et al,11
2010
14 64 49 NR 71 Retrospective
single-center
Median, 16
(range,
8-24) wk
Variable Median, 10
(range,
4-22) mo
Failure to achieve or maintain
$PASI50 for $12 wk
Yamauchi
and Mau,19
2009
12 58 38 8 50 Prospective
case series
12 wk 1 wk #24 wk PASI75 achieved at wk 12, but
unable to maintain with
step-down dosing
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Table I. Cont’d
Study N Men, %
Mean
age, y
Mean disease
duration, y
PsA
history,
% Study type
Study
duration
Washout
period
Mean duration
of first TNF
antagonist Failure definition
Martyn-
Simmons
et al,20
2009
5 80 47 21 40 Prospective OL 12 wk 4-38 wk
(Mean,
13 wk)
NR Not achieving PASI50 after
$12 wk of therapy
ETA to IFX
Gottlieb
et al,9
2012
215 64 44 6 13 19 6 11 NR Prospective OL 26 wk 2 wk NR ‘‘Persistence of disease that
impacted HRQoL, as
determined by the investigator’’
Ayala
et al,22
2015
38 74 47 6 10 NR 32 Prospective OL 28 wk $3 wk #24 wk Resistant: No PASI score reduction
or an increase in BSA affected by
psoriasis after 12 wk of therapy
Failure: No PASI75 or BSA $10%
after 24 wk of therapy
Haitz and
Kalb,10
2007
19 NR 50 NR NR Retrospective 16 wk 0 (for 17
Patients)
Unclear if
17-mo (range,
1-36 mo)
‘‘treatment’’ is
for ETA, IFX,
or both
‘‘No specified definition. [mostly]
based on physician evaluation
or patient concern regarding a
lack of treatment response or
worsening disease’’
ADA to ETA
Vender,17
2011
10 50 42 15 30 Prospective OL 24 wk 11-17 d 19 (range,
6-36) mo
PGA score $2 after $12 wk
Multiple switch types
Ortonne
et al,18
2011y
282 65 46 22 34 Double-blind
RCT subset
16 wk 3-8 wk NR For ‘‘biologics’’: ‘‘never achieved a
satisfactory response’’;
‘‘achieved a satisfactory response
initially, but lost it over time’’;
‘‘discontinued treatment because
of intolerance/side effects’’
Papp
et al,8
2012z
203 61 46 22 37 Prospective OL 24 wk
Minimum
NR NR ‘‘Never achieving satisfactory
response or achieving satisfactory
response initially, but losing it
over time’’ and PGA score $2
Piaserico
et al,21
2014
105 65 47 6 13 NR NR Registry data
extraction
52 wk NR 29.0 6 26.4 wk 18: PASI75 never achieved (n = 47)
28: Loss of initial PASI75 response
(n = 23)
AE/other (n = 35)
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Table I. Cont’d
Study N Men, %
Mean
age, y
Mean disease
duration, y
PsA
history,
% Study type
Study
duration
Washout
period
Mean duration
of first TNF
antagonist Failure definition
Bissonnette
et al,16
2015
Prospective 24 wk 2 wk
ADA to
ETA (18)
37 76 51 6 11 NR NR NR PGA score $2 after 12 wk of therapy
ADA to
ETA (28)
30 70 47 6 13 NR NR NR Achieved PGA score 0/1 at wk 12
but subsequently lost response
IFX to
ETA (28)
14 79 46 6 12 NR NR NR Achieved PGA score 0/1 after $3
infusions but subsequently lost
response any time after infusion 3
ADA, Adalimumab; AE, adverse event; BSA, body surface area; ETA, etanercept; HRQoL, health-related quality of life; IFX, infliximab; NR, not reported; OL, open-label; PASI, Psoriasis Area and Severity
Index; PASI50, 50% improvement in PASI score; PASI75, 75% improvement in PASI score; PGA, Physician Global Assessment; PsA, psoriatic arthritis; RCT, randomized controlled trial; TNF, tumor
necrosis factor; 18, primary failure; 28, secondary failure.
*Includes patients with 18 (n = 50 [36 men]) and 28 (n = 35 [24 men]) ETA failure.
yInformation available only for all patients with prior antieTNF exposure (n = 282), but fewer were exposed to ETA (n = 170) or IFX (n = 53); 195 patients had experienced failure of prior therapy.
zInformation listed for patients who failed to respond to any prior therapies; however, only a subset of these patients (n = 17) failed to respond to IFX or ETA.
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Table II. Efficacy outcomes of included studies
Study N Failure type
PGA 0/1, % of patients PASI75, % of patients PASI50, % of patients Mean DLQI change
12 wk 16 wk 24 wk 12 wk 16 wk 24 wk
48/52
wk 12 wk 16 wk 24 wk
48/52
wk 16 wk 24 wk
ETA to ADA
Strober
et al,14
2011
82 18, 28 d 49 d d d d d d d d d 3.8 d
Bissonnette
et al,15
2010
50 18 34 d 46 40 d 52 d d d d d d d
Bissonnette
et al,15
2010
35 28 31 d 46 31 d 63 d d d d d d d
Fonseca
et al,13
2015
35 18, 28,
Intolerance
d d d 77 d 71 69 83 d 74 74 d d
van L€umig
et al,12
2010
30 18, 28,
Intolerance
d d d 27 d 36 54 70 d 61 77 d d
Woolf
et al,11
2010
14 18, 28 d d d d 29 d d d 64 d d 4.9 d
Yamauchi
and Mau,19
2009
12 28 d d d 58 d d 92 d d d d d d
Martyn-
Simmons
et al,20
2009
5 18 d d d 40 d d d 80 d d d 8.8
(12 wk)
d
ETA/IFX to ADA
Ortonne
et al,18
2011
80* 18 d d d d 54 d d d d d d d d
Ortonne
et al,18
2011
99* 28 d d d d 66 d d d d d d d d
Ortonne
et al,18
2011
16* Intolerance d d d d 50 d d d d d d d d
Continued
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
S
E
P
T
E
M
B
E
R
20
16
6
1
8
.e
4
Y
a
m
a
u
ch
i
et
a
l
Table II. Cont’d
Study N Failure type
PGA 0/1, % of patients PASI75, % of patients PASI50, % of patients Mean DLQI change
12 wk 16 wk 24 wk 12 wk 16 wk 24 wk
48/52
wk 12 wk 16 wk 24 wk
48/52
wk 16 wk 24 wk
Piaserico
et al,21
2014
43 18, 28,
Intolerance
d d d d 38 58 d d d d d d d
Papp
et al,8
2012y
17 18, 28,
Intolerance
d 21 21 d 71 59 d d d d d d d
ETA to IFX
Gottlieb
et al,9
2012
215 18, 28 65 (10 wk) d 61 (26 wk) 52 (10 wk) d 55 (26 wk) d 79 (10 wk) d 65 (26 wk) d 7.1 (10 wk) 7.5 (26 wk)
Ayala
et al,22
2015
38 18 d d d 71 (10 wk) 94 (18 wk) 74 d 91 (10 wk) 97 (18 wk) 89 d d 13
Haitz and
Kalb,10
2007
19 18, 28 37 d d d d d d d d d d d d
ADA/ETA to IFX
Piaserico
et al,21
2014
39 18, 28,
Intolerance
d d d d 27 40 d d d d d d d
ADA to ETA
Bissonnette
et al,16
2015
30 18 20 d 20 d d d d d d d d d 3.5
Bissonnette
et al,16
2015
37 28 38 d 35 d d d d d d d d d 6.4
Vender,17
2011
10 18 50 d 70 d d d d d d d d 5.8 (12 wk) 5.1
ADA/IFX
to ETA
Piaserico
et al,21
2014
23 18, 28,
Intolerance
d d d d 14 30 d d d d d d d
IFX to ETA
Bissonnette
et al,16
2015
14 28 36 d 36 d d d d d d d d d 6.7
ADA, Adalimumab; DLQI, Dermatology Life Quality Index; ETA, etanercept; IFX, infliximab; PASI, Psoriasis Area and Severity Index; PASI50, 50% improvement in PASI score; PASI75, 75% improvement
in PASI score; PGA, Physician Global Assessment; 18, primary failure; 28, secondary failure; d, not reported.
*Data combined for patients who failed ETA, IFX, or another antietumor necrosis factor agent.
yPGA response for patients who failed ETA (n = 14); PASI75 response for patients who failed IFX or ETA (n = 17).
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Table III. Safety outcomes of included studies
Study N
Patients with
AE, n (%)
Patients with
serious AE, n (%)
Patients with
infectious AE, n (%)
Discontinued because
of AE, n (%) Notes
ETA to ADA
Strober et al,14 2011 82 45 (55) 4 (5) 13 (16) 0 ‘‘No deaths, malignancies (of any type), TB, demyelinating
disease, CHF, lupuslike syndrome, or opportunistic
infections occurred’’
Bissonnette et al,15
2010*
85 n = 154 [4.1/
patient-year]
0 n = 46 [1.2/
patient-year]
0 No TB, demyelination, cancer or CHF; however, patients
with symptoms of demyelinating disease and TB were
excluded at screening
Fonseca et al,13 2015 35 NR NR NR 0 Patients excluded for TB
van L€umig et al,12
2010
30 [3.2/patient-year] [0.2/patient-year] [0.9/patient-year;
0 Serious]
NR
Woolf et al,11 2010 14 5 (36) 0 NR NR
Yamauchi and Mau,19
2009
12 0 0 0 0 No TB, demyelination, CHF, hepatitis B, malignancies, or
lymphoma
Martyn-Simmons
et al,20 2009
5 NR 0 NR NR
ETA to IFX
Gottlieb et al,9 2012 215 148 (69) 8 (4) 71 (33);
1 Serious
19 (9) No TB; 2 squamous cell carcinomas (forearm, cervix [n = 1
each]); ischemic coronary artery disease (n = 1); infective
bursitis and cellulitis (n = 1); infusion reactions in 7%
Ayala et al,22 2015 38 20 (53) 4 (11) NR 3 (8)
Haitz and Kalb,10 2007 19 16 Events $2 ($11) Unclear (possibly
n = 9)
Unclear (n $ 2) 2 Patients died secondary to myocardial infarction; ‘‘no
unusual infections’’
ADA to ETA
Vender,17 2011 10 2 (20) 0 NR NR
Multiple switch types
Ortonne et al,18 2011y 282 180 (64) 11 (4) 83 (29)
Serious, 6 (2)
opportunistic, 3 (1)
5 (2) No deaths, TB, demyelinating disease, lupus or lupuslike
syndromes, or CHF
Papp et al,8 2012z 203 145 (71)
[4.7/patient-year]
9 (4)
[0.1/patient-year]
85 (42)
[1.4/patient-year]
Serious, 2 (1)
[0.02/patient-year]
9 (4) [0.1/
patient-year]
No lymphoma, malignancy other than lymphoma or NMSC,
demyelinating disorders, TB, lupuslike syndrome, or
CHF; 2 unrelated deaths
Piaserico et al,21 2014 23 NR NR NR NR
Bissonnette
et al,16 2015x
81 NR 2 (3) NR NR
ADA, Adalimumab; AE, adverse event; CHF, congestive heart failure; ETA, etanercept; IFX, infliximab; NMSC, nonmelanoma skin cancer; NR, not reported; TB, tuberculosis.
*Includes patients with primary (n = 50) and secondary (n = 35) ETA failure.
yData for all patients with prior antietumor necrosis factor exposure (n = 282), including ETA (n = 170) and IFX (n = 53).
zData for all patients who failed to respond to any prior therapies; however, only a subset of these patients (n = 17) failed to respond to IFX or ETA.
xIncludes patients with primary (n = 30) and secondary (n = 37) ADA failure and patients with secondary IFX failure (n = 14).
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
S
E
P
T
E
M
B
E
R
20
16
6
1
8
.e
6
Y
a
m
a
u
ch
i
et
a
l
